NCLEX Review Guide: Muscle Relaxants

Centrally Acting Muscle Relaxants

• These medications act on the central nervous system (CNS) to reduce muscle tone and spasticity without affecting neuromuscular transmission. They primarily depress synaptic responses in the spinal cord and potentially in higher centers.
• Common examples include baclofen, cyclobenzaprine, tizanidine, and methocarbamol, which are typically used for muscle spasms, pain, and spasticity associated with musculoskeletal conditions.

Neuromuscular Blocking Agents

• These agents act at the neuromuscular junction to block acetylcholine from binding to receptors on the skeletal muscle, preventing muscle contraction. They are primarily used in surgical procedures for muscle paralysis during intubation and to maintain surgical relaxation.
• Two main categories exist: depolarizing agents (e.g., succinylcholine) which initially stimulate then block receptors, and non-depolarizing agents (e.g., rocuronium, vecuronium, pancuronium) which competitively block receptors without initial stimulation.

Direct-Acting Skeletal Muscle Relaxants

• These medications act directly on skeletal muscle to interfere with calcium release from the sarcoplasmic reticulum, preventing muscle contraction. The primary example is dantrolene, which is used for malignant hyperthermia and chronic spasticity conditions.
• Unlike other muscle relaxants, dantrolene works peripherally on the muscle tissue itself rather than on the nervous system or neuromuscular junction.

Baclofen (Lioresal)

• Baclofen is a GABA-B receptor agonist that inhibits both monosynaptic and polysynaptic reflexes at the spinal cord level. It's primarily indicated for spasticity associated with multiple sclerosis, spinal cord injuries, and other spinal cord disorders.
• Available in oral form and as intrathecal therapy through implanted pumps for severe, chronic spasticity when oral therapy is ineffective or produces intolerable side effects.

Cyclobenzaprine (Flexeril)

• Structurally related to tricyclic antidepressants, cyclobenzaprine acts primarily at the brain stem to reduce tonic muscle activity. It's indicated for short-term relief (2-3 weeks) of muscle spasms associated with acute, painful musculoskeletal conditions.
• Not effective for spasticity associated with cerebral or spinal cord disease, as it works best for acute conditions rather than chronic neurological disorders.

Succinylcholine (Anectine)

• A depolarizing neuromuscular blocking agent that acts as an acetylcholine receptor agonist, causing sustained depolarization of the motor end plate. It has an ultra-short duration of action (5-10 minutes) making it ideal for brief procedures requiring rapid intubation.
• Metabolism occurs rapidly via plasma pseudocholinesterase, which hydrolyzes the drug into inactive metabolites.

Assessment & Monitoring

• For centrally acting relaxants, assess baseline vital signs, pain levels, range of motion, and functional ability before administration. Monitor for sedation, dizziness, and hypotension, especially with initial doses or dose increases.
• For neuromuscular blocking agents, continuous monitoring of vital signs, oxygen saturation, and degree of neuromuscular blockade using peripheral nerve stimulator is essential. Ensure ventilatory support is available and functioning properly.

Administration Considerations

1. Verify the correct medication, dose, route, and patient using two identifiers before administration.
2. For oral muscle relaxants, administer with food if GI upset occurs, but be consistent with relation to meals.
3. For IV neuromuscular blockers, administer through a dedicated IV line when possible to prevent incompatibilities.
4. Have emergency equipment readily available when administering neuromuscular blocking agents, including ventilation equipment and reversal agents.
5. Document response to medication, including muscle tone, pain relief, and any adverse effects.

Patient Education

• Instruct patients taking centrally acting muscle relaxants to avoid alcohol and other CNS depressants, which can potentiate sedative effects and increase risk of respiratory depression.
• Educate patients on the importance of gradual dose reduction when discontinuing therapy, especially for baclofen, to prevent withdrawal symptoms.

Common Pitfalls to Avoid

• Confusing paralysis with sedation: Neuromuscular blocking agents cause paralysis without sedation or analgesia. Patients receiving these agents must also receive sedation and pain management.
• Overlooking drug interactions: Many centrally acting muscle relaxants have significant interactions with other CNS depressants, leading to enhanced sedation and respiratory depression.
• Inadequate monitoring: Failure to use peripheral nerve stimulators to monitor neuromuscular blockade can result in awareness during procedures or inadequate reversal.

Quick Check Questions

Self-Assessment Checklist

• I can differentiate between centrally acting muscle relaxants and neuromuscular blocking agents
• I understand the major side effects and nursing considerations for common muscle relaxants
• I can identify the signs of baclofen withdrawal
• I understand the monitoring requirements for patients receiving neuromuscular blocking agents
• I can explain the mechanism of action for depolarizing vs. non-depolarizing muscle relaxants
• I know which patients are at risk for complications with succinylcholine